MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm, Inc. (“Pediapharm”) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CDN$60 million.

Pediapharm logo

PEDIAPHARM is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community.

Medexus logo

MEDEXUS is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada.

Medac Pharm logo

MEDAC PHARMA is a specialty pharmaceutical company focusing on the development and commercialization of treatments for autoimmune diseases and oncology in the United States.


What's New

March 8, 2019
Medexus to Present at the 2019 LD Micro Virtual Conference
Read More >

March 6, 2019
Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada
Read More >

March 4, 2019
Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada
Read More >


Medexus Pharmaceuticals Inc., D, TSXV